With the approval of EmbryoScope in China, Vitrolife enters an exciting year. Accounting for limitations in production capacity and a divesture of certain low margin products, however, we lower our estimates for 2018. Following the updates in our model, we lower our base case to 610 (620) per share. Bull case and bear case are SEK 760 and SEK 400 per share, respectively.